SGN-B6A is an ADC, which targets integrin beta-6 ( ITGB6 ) through human IgG1 monoclonal antibody Sigvotatug, and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE [1].
References:
[1]. Lyon RP, et al., SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications. Mol Cancer Ther. 2023 Dec 1;22(12):1444-1453.
References:
[1]. Lyon RP, et al., SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications. Mol Cancer Ther. 2023 Dec 1;22(12):1444-1453.
















